secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirati Therapeutics, Inc. (—)
CIK:        0001576263
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0001628280-23-030373
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirati Therapeutics CFO Stelzer to depart Sept 8; Aaron Ondrey named interim CFO
--------------------------------------------------------------------------------

- CFO Laurie Stelzer resigns effective Sept 8, 2023 to pursue opportunity at another biotech; will consult through Oct 2023.
- Aaron Ondrey (SVP FP&A since July 2022) appointed interim CFO; base salary increased to $450k.
- Ondrey receives retention award: $300k cash plus $300k in RSUs vesting 90 days after permanent CFO hired.
- Mirati recently completed an upsized public offering, extending cash runway through upcoming milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576263/000162828023030373/0001628280-23-030373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576263/000162828023030373/mrtx-20230817.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-030373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer